Key result
Coxsackievirus type B3 selectively lysed KRAS mutant lung adenocarcinoma cells in vitro and caused marked tumor regression in mouse xenograft models.
Why the study?
KRAS-mutant lung adenocarcinoma is a refractory cancer lacking targeted therapy, prompting exploration of coxsackievirus type B3 as an oncolytic treatment.
Does Coxsackievirus type B3 induce tumor regression in KRAS-mutant lung adenocarcinoma models?
Does Coxsackievirus type B3 induce tumor regression in KRAS-mutant lung adenocarcinoma models?
Coxsackievirus type B3 selectively kills KRAS-mutant lung adenocarcinoma cells and induces marked tumor regression in mouse models, highlighting its potential as an oncolytic viral therapy.
This is the authors' abstract. We don't add key points for this paper.
KRAS mutant ( KRAS mut ) lung adenocarcinoma is a refractory cancer without available targeted therapy. The current study explored the possibility to develop coxsackievirus type B3 (CVB3) as an oncolytic agent for the treatment of KRAS mut lung adenocarcinoma. In cultured cells, we discovered that CVB3 selectively infects and lyses KRAS mut lung adenocarcinoma cells (A549, H2030, and H23), while sparing normal lung epithelial cells (primary, BEAS2B, HPL1D, and 1HAEo) and EGFR mut lung adenocarcinoma cells (HCC4006, PC9, H3255, and H1975). Using stable cells expressing a single driver mutation of either KRAS G12V or EGFR L858R in normal lung epithelial cells (HPL1D), we further showed that CVB3 specifically kills HPL1D- KRAS G12V cells with minimal harm to HPL1D- EGFR L858R and control cells. Mechanistically, we demonstrated that aberrant activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and compromised type I interferon immune response in KRAS mut lung adenocarcinoma cells serve as key factors contributing to the sensitivity to CVB3-induced cytotoxicity. Lastly, we conducted in vivo xenograft studies using two immunocompromised mouse models. Our results revealed that intratumoral injection of CVB3 results in a marked tumor regression of KRAS mut lung adenocarcinoma in both non-obese diabetic (NOD) severe combined immunodeficiency (SCID) gamma (NSG) and NOD-SCID xenograft models. Together, our findings suggest that CVB3 is an excellent candidate to be further developed as a targeted therapy for KRAS mut lung adenocarcinoma.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for CVB3 oncolysis in KRAS mut lung adenocarcinoma; prospective trials needed before clinical adoption.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2019) studied KRAS mutant lung adenocarcinoma. Coxsackievirus type B3 (CVB3) was evaluated on Tumor regression and cytotoxicity. Coxsackievirus type B3 selectively lysed KRAS mutant lung adenocarcinoma cells in vitro and caused marked tumor regression in mouse xenograft models.
Synapse has enriched 10 related papers. Consider them for comparative context: